Faron Pharmaceuticals Oy

Established in Turku, Finland, in 2003, Faron Pharmaceuticals Oy operates as a clinical-stage biotechnology firm dedicated to the discovery and advancement of novel pharmaceutical solutions. The company's core focus lies in harnessing immune modulation to develop proprietary drug candidates addressing significant unmet medical needs. Their pipeline spans critical areas such as immuno-oncology, organ safeguarding, and regenerative medicine. Among its leading therapeutic candidates is Traumakine, an intravenous interferon beta-1a treatment under investigation for conditions including acute respiratory distress syndrome (ARDS), COVID-19, acute kidney injury, cardiac protection, solid organ transplant, and ischemia reperfusion injury. Another key asset is Bexmarilimab, an innovative precision cancer immunotherapy designed to target solid tumors, non-small cell lung carcinoma, and hematological malignancies. Additionally, Faron is developing Haematokine, a new chemical entity acting as an AOC3 inhibitor, aimed at treating hematological malignancies and bone marrow-related conditions.

Faron Pharmaceuticals Oy trades as FARN.L on LSE. The company is classified in Healthcare / Biotechnology and reports in GBP.

The current profile places the business in Biotechnology. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows £0 of revenue and -£27.25M of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Faron Pharmaceuticals Oy can be compared against peers such as 4basebio PLC, Avacta Group Plc, Bioventix PLC, Beximco Pharmaceuticals Limited, Hemogenyx Pharmaceuticals Plc, ImmuPharma plc.

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of £49.61M, beta of 1.11, and return on equity of +147.3%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

FARN.L currently shows total debt of £24.67M and beta of 1.11. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.faron.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.